Transforming
Science Into Impact

We are advancing a late-stage pipeline of next-generation therapies for immune-mediated diseases, moving beyond broad immunosuppression to deliver targeted treatments that can be used alone or in combination therapy.

Pipeline

Product
Target
Indication

Envudeucitinib

TYK2

TYK2
Plaque Psoriasis
    
Systemic Lupus Erythematosus
    

Lonigutamab

IGF-1R

IGF-1R
Thyroid Eye Disease
    

A-005

TYK2

TYK2
Neuroinflammation
    

Undisclosed

IRF5, Additional Targets

IRF5, Additional Targets
Undisclosed
    

Global Rights
Alumis retains global rights for all except envudeucitinib where the rights for Plaque Psoriasis are shared with Kaken in Japan